Oncolytics Biotech Inc. (TSE:ONC – Get Rating) – Leede Jones Gab issued their FY2023 earnings per share estimates for Oncolytics Biotech in a note issued to investors on Monday, March 6th. Leede Jones Gab analyst D. Loe anticipates that the company will post earnings per share of ($0.36) for the year. The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share. Leede Jones Gab also issued estimates for Oncolytics Biotech’s FY2024 earnings at ($0.33) EPS, FY2025 earnings at ($0.31) EPS and FY2026 earnings at ($0.02) EPS.
Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a C$9.00 target price on shares of Oncolytics Biotech in a research note on Monday.
Oncolytics Biotech Stock Down 5.6 %
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies.
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.